Endpoints News Mar 14, 2026 Roche’s breast cancer failure; BioNTech co-founders to depart; Eli Lilly’s quest to stay on top; and more
Endpoints News Mar 13, 2026 Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease
Endpoints News Mar 13, 2026 Flagship startup loses CEO to Ipsen; Ionis to shed nearly six decades of board experience
Endpoints News Mar 12, 2026 A simpler form of DNA may be key to non-viral gene therapy, study suggests
Endpoints News Mar 12, 2026 Sandoz reorg ahead of 'golden decade' for biosimilars; Sanofi to shed Latin America generics business
Endpoints News Mar 12, 2026 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News Mar 12, 2026 Novo Holdings’ assets fell by a third in 2025 as Novo Nordisk’s value sank